Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director · President and CEO | April 27, 2017 | May 01, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZIMMER BIOMET HOLDINGS, INC.
Report date April 27, 2017 · Filed May 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 294,555 |
Ending reported balance
After 2017-04-27 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-04-27 · Exercise / conversion · Acquired 100,000 · Balance 381,886 F1: Securities acquired pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. Row 2 · 2017-04-27 · Sale · Disposed 52,784 · Balance 329,102 F2: Securities sold to cover option exercise cost, taxes and fess pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. F3: Represents the sale of 52,784 shares in multiple transactions, ranging in price from $115.46 to $116.45 per share, resulting in a weighted average sale price of $116.13. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Row 3 · 2017-04-27 · Sale · Disposed 34,547 · Balance 294,555 F2: Securities sold to cover option exercise cost, taxes and fess pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. F4: Represents the sale of 34,547 shares in multiple transactions, ranging in price from $116.46 to $117.07 per share, resulting in a weighted average sale price of $116.99. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.76 · Expires 2017-04-30 | Direct | 0 |
Reported balance
After 2017-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-04-27 · Exercise / conversion · Disposed 100,000 · Balance 0 F5: Vested annually over four years in increments of 25% each year, commencing on May 1, 2008. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities acquired pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016.
F2: Securities sold to cover option exercise cost, taxes and fess pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016.
F3: Represents the sale of 52,784 shares in multiple transactions, ranging in price from $115.46 to $116.45 per share, resulting in a weighted average sale price of $116.13. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
F4: Represents the sale of 34,547 shares in multiple transactions, ranging in price from $116.46 to $117.07 per share, resulting in a weighted average sale price of $116.99. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
F5: Vested annually over four years in increments of 25% each year, commencing on May 1, 2008.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ST JUDE MEDICAL, LLC
Report date January 04, 2017 · Filed January 06, 2017
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Disposition to issuer · Disposed 5,599 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2017 Filed May 1, 2017 20:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $88.76 | $0.00 |
DisclosureSEC source: 0000911916-17-000165 · edgar.xml · derivative · entry 4 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2017-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Vested annually over four years in increments of 25% each year, commencing on May 1, 2008. Read SEC document |
| April 27, 2017 Filed May 1, 2017 20:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 34,547 | $116.99 | $4,041,653.53 |
DisclosureSEC source: 0000911916-17-000165 · edgar.xml · nonDerivative · entry 3 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,555 F2 · shares: Securities sold to cover option exercise cost, taxes and fess pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. F4 · price: Represents the sale of 34,547 shares in multiple transactions, ranging in price from $116.46 to $117.07 per share, resulting in a weighted average sale price of $116.99. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2017 Filed May 1, 2017 20:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 52,784 | $116.13 | $6,129,805.92 |
DisclosureSEC source: 0000911916-17-000165 · edgar.xml · nonDerivative · entry 2 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,102 F2 · shares: Securities sold to cover option exercise cost, taxes and fess pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. F3 · price: Represents the sale of 52,784 shares in multiple transactions, ranging in price from $115.46 to $116.45 per share, resulting in a weighted average sale price of $116.13. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2017 Filed May 1, 2017 20:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 100,000 | $88.76 | $8,876,000.00 |
DisclosureSEC source: 0000911916-17-000165 · edgar.xml · nonDerivative · entry 1 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Securities acquired pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. Read SEC document |
| March 21, 2017 Filed Mar 23, 2017 20:57 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantEmployee Stock Option (right to buy) · Derivative | 145,350 | $0.00 Strike: $121.88 | $0.00 |
DisclosureSEC source: 0000911916-17-000121 · edgar.xml · derivative · entry 1 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,350 Underlying: Common Stock · 145,350 shares Expires 2027-03-21 F1 · derivative.exercise_date: Vests annually over four years in increments of 25% each year, commencing on March 21, 2018. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 19:09 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 1,040 | $121.63 | $126,495.20 |
DisclosureSEC source: 0000911916-17-000115 · edgar.xml · nonDerivative · entry 3 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,886 F2 · shares: Securities sold to cover additional taxes on the vesting of restricted stock units pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. F3 · price: Represents the sale of 1,040 shares in multiple transactions, ranging in price from $121.55 to $121.69 per share, resulting in a weighted average sale price of $121.627. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 19:09 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionRestricted Stock Units · Derivative | 23,929 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-17-000115 · edgar.xml · derivative · entry 4 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F5 · derivative.exercise_date: The earned RSUs vested on March 17, 2017. F5 · derivative.expiration_date: The earned RSUs vested on March 17, 2017. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 19:09 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Tax withholdingCommon Stock | 11,151 | $120.47 | $1,343,360.97 |
DisclosureSEC source: 0000911916-17-000115 · edgar.xml · nonDerivative · entry 2 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,926 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 19:09 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 23,929 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-17-000115 · edgar.xml · nonDerivative · entry 1 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 19:49 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 23,929 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-17-000054 · edgar.xml · derivative · entry 1 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,929 Underlying: Common Stock · 23,929 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: On March 17, 2014, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2014 - 2016. As determined on February 9, 2017, based on the Company's actual performance for 2014 - 2016, the reporting person earned 23,929 RSUs. F3 · derivative.exercise_date: Earned RSUs will vest on March 17, 2017. F3 · derivative.expiration_date: Earned RSUs will vest on March 17, 2017. F2 · derivative.underlying_shares: On March 17, 2014, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2014 - 2016. As determined on February 9, 2017, based on the Company's actual performance for 2014 - 2016, the reporting person earned 23,929 RSUs. F2 · balance_after: On March 17, 2014, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2014 - 2016. As determined on February 9, 2017, based on the Company's actual performance for 2014 - 2016, the reporting person earned 23,929 RSUs. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:19 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $83.68 | $0.00 |
DisclosureSEC source: 0000911916-17-000040 · edgar.xml · derivative · entry 3 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,500 shares Expires 2017-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Vested annually over four years in increments of 25% each year, commencing on February 6, 2008. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:19 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 43,207 | $117.77 | $5,088,561.84 |
DisclosureSEC source: 0000911916-17-000040 · edgar.xml · nonDerivative · entry 2 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,148 F3 · shares: Securities sold to cover option exercise cost, taxes and fess pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. F4 · price: Represents the sale of 43,207 shares in multiple transactions, ranging in price from $117.26 to $118.23 per share, resulting in a weighted average sale price of $117.7717. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 21:19 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 52,500 | $83.68 | $4,393,200.00 |
DisclosureSEC source: 0000911916-17-000040 · edgar.xml · nonDerivative · entry 1 DVORAK DAVID C · CIK 0001239000 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Securities acquired pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016. F2 · balance_after: Includes 269 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan between May 2, 2016 and January 30, 2017. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:45 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerCommon Stock | 5,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000610 · edgar.xml · nonDerivative · entry 1 DVORAK DAVID C · CIK 0001239000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.